We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High sdLDL-C and Lipoprotein(A) Levels Correlated to Coronary Arteriostenosis in Takayasu Arteritis

By LabMedica International staff writers
Posted on 11 Nov 2021
Print article
Image: The Beckman AU5400 automatic biochemical analyzer (Photo courtesy of Beckman Coulter)
Image: The Beckman AU5400 automatic biochemical analyzer (Photo courtesy of Beckman Coulter)
Takayasu arteritis (TA) is a rare vasculitis that mainly involves the aorta and its major branches. TA is mainly seen in young women aged 20–40 years and is most often encountered in Japan, Southeast Asia, India, and Mexico. Due to nonspecific clinical features, TA patients with coronary arteriostenosis might be misdiagnosed or inappropriately treated.

Dyslipidemia plays a role in the pathogenesis of TA, and the lipid profiles in TA patients are pro-atherogenic. Small dense low-density lipoprotein cholesterol (sdLDL-C) is small and highly dense relative to other LDL-C particles and thought to be more atherogenic than the large buoyant LDL (lb-LDL) due to greater penetration into the arterial wall, a prolonged plasma half-life, lower hepatic LDL receptor affinity, and higher susceptibility to oxidation.

Clinical Laboratorians at the Capital Medical University (Beijing, China) retrospectively studied 190 TA patients and 154 healthy subjects. TA patients were divided into three categories based on the degree of coronary stenosis: Group I, stenosis >50%; Group II, stenosis 1%–50%; and Group III, stenosis 0%. Independent risk factors for coronary arteriostenosis in TA were identified by logistic regression, followed by receiver operating characteristic curve analysis to determine the specificity and sensitivity of risk factors and Youden's Index score calculation to determine the cutoff points.

The team obtained early in the morning, venous blood samples were from fasting TA patients and healthy controls. The team previously compared methods for measuring sdLDL-C, and a Beckman AU5400 automatic biochemical analyzer (Beckman Coulter, Brea, CA, USA) and was used in the present study to measure novel and traditional lipid parameters and biochemical indicators, including the sdLDL-C, Lp(a), total cholesterol (TC), LDL-C, HDL-C, and triglyceride (TG) concentrations within 5–6 hours after sample collection. The Sysmex XE-2100 (Sysmex Corporation, Kobe, Japan) was used to determine complete blood counts.

The investigators reported Takayasu arteritis patients had significantly higher serum levels of sdLDL-C and Lp(a) than healthy controls. The total cholesterol, triglyceride, LDL-C, sdLDL-C, and Lp(a) levels and the sdLDL-C/LDL-C ratio in Group I were significantly higher than those in Groups II and III. An elevated serum sdLDL-C level elevated the risk of coronary arteriostenosis by 5-fold (cutoff value, 0.605 mmol/L). An increased serum Lp(a) level increased the risk of coronary arteriostenosis by 3.9-fold (cutoff value, 0.045 g/L). An elevated sdLDL-C/LDL-C ratio increased the risk of coronary arteriostenosis by 2.1-fold (cutoff value, 0.258).

The authors concluded that TA patients had higher serum sdLDL-C and Lp(a) concentrations than healthy individuals and TA patients with coronary arteriostenosis had significantly higher serum levels of sdLDL-C and Lp(a) than those without coronary arteriostenosis. Additionally, serum sdLDL-C and Lp(a) concentrations and the sdLDL-C/LDL-C ratio might be used as diagnostic factors for coronary arteriostenosis in TA patients. The study was published on October 28, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Capital Medical University
Beckman Coulter
Sysmex Corporation


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.